{"id":45556,"date":"2025-11-03T11:12:24","date_gmt":"2025-11-03T03:12:24","guid":{"rendered":"https:\/\/flcube.com\/?p=45556"},"modified":"2025-11-03T11:12:25","modified_gmt":"2025-11-03T03:12:25","slug":"fda-cder-director-george-tidmarsh-placed-on-leave-amid-probe-over-drug%e2%80%91approval-program-concerns","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45556","title":{"rendered":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns"},"content":{"rendered":"\n<p>The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (<strong>CDER<\/strong>) confirmed that <strong>George\u202fTidmarsh<\/strong>, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-facts\">Key Facts<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Who:<\/strong> George\u202fTidmarsh \u2013 Director, FDA CDER; former biotech executive and adjunct professor at Stanford School of Medicine.<\/li>\n\n\n\n<li><strong>When:<\/strong> Placed on leave <strong>effective immediately<\/strong> (announcement reported by the <em>New\u202fYork\u202fTimes<\/em>).<\/li>\n\n\n\n<li><strong>Why:<\/strong><\/li>\n\n\n\n<li>Raised objections to a rapid\u2011approval program for new drugs.<\/li>\n\n\n\n<li>Allegations surfaced that he may have used regulatory authority to retaliate against a firm connected to a former associate.<\/li>\n\n\n\n<li><strong>Investigation:<\/strong> An internal FDA review is underway; no formal findings have been released.<\/li>\n\n\n\n<li><strong>Background:<\/strong><\/li>\n\n\n\n<li>Appointed CDER head in <strong>July\u202f2025<\/strong>, succeeding Vinay\u202fPrasad, who departed abruptly.<\/li>\n\n\n\n<li>CDER is the FDA\u2019s largest branch, overseeing all OTC and prescription drug approvals.<\/li>\n\n\n\n<li>Tidmarsh\u2019s tenure began as <strong>Sarepta Therapeutics<\/strong> faced heightened scrutiny of its gene\u2011therapy portfolio, including the flagship product <strong>Elevidys<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-context-amp-implications\">Context &amp; Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fast\u2011Track Approval Program:<\/strong> Designed to accelerate market entry for promising therapies, the program has drawn criticism from some regulators who fear compromised safety reviews.<\/li>\n\n\n\n<li><strong>Regulatory Oversight:<\/strong> The leave underscores the FDA\u2019s heightened sensitivity to potential conflicts of interest and the importance of maintaining public trust in the drug\u2011approval process.<\/li>\n\n\n\n<li><strong>Industry Reaction:<\/strong> Stakeholders are monitoring the situation closely, as any shift in CDER leadership could affect pending drug reviews and the broader regulatory timeline for innovative therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-s-next\">What\u2019s Next<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The FDA is expected to issue a formal statement within the next 48\u202fhours outlining the scope of the investigation and any interim leadership arrangements at CDER.<\/li>\n\n\n\n<li>Congressional committees may request briefings on the matter, given the implications for drug\u2011policy and public\u2011health oversight.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual outcomes may differ materially from those expressed herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45557,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[],"class_list":["post-45556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45556\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45556\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T03:12:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T03:12:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns\",\"datePublished\":\"2025-11-03T03:12:24+00:00\",\"dateModified\":\"2025-11-03T03:12:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0302.webp\",\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45556#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45556\",\"name\":\"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0302.webp\",\"datePublished\":\"2025-11-03T03:12:24+00:00\",\"dateModified\":\"2025-11-03T03:12:25+00:00\",\"description\":\"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45556\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45556#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45556","og_locale":"en_US","og_type":"article","og_title":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns","og_description":"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.","og_url":"https:\/\/flcube.com\/?p=45556","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-03T03:12:24+00:00","article_modified_time":"2025-11-03T03:12:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45556#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45556"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns","datePublished":"2025-11-03T03:12:24+00:00","dateModified":"2025-11-03T03:12:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45556"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45556#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45556#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45556","url":"https:\/\/flcube.com\/?p=45556","name":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45556#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45556#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","datePublished":"2025-11-03T03:12:24+00:00","dateModified":"2025-11-03T03:12:25+00:00","description":"The U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) confirmed that George\u202fTidmarsh, the agency\u2019s director, has been placed on administrative leave. The move follows internal concerns he raised about a newly\u2011launched \u201cfast\u2011track\u201d drug\u2011approval initiative and a subsequent investigation into alleged retaliation against a company linked to a former business associate. The FDA has not yet disclosed the specifics of the leave or the status of the investigation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45556#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45556"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45556#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","width":1080,"height":608,"caption":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45556#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA CDER Director George\u202fTidmarsh Placed on Leave Amid Probe Over Drug\u2011Approval Program Concerns"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45556"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45556\/revisions"}],"predecessor-version":[{"id":45558,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45556\/revisions\/45558"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45557"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}